Structure Therapeutics reported positive Phase 1/2a SAD data for its amylin agonist ACCG-2671 and 72-week OLE data for GLP-1 agonist aleniglipron, showing weight loss without plateau. The company also initiated Phase 3 trials and confirmed upcoming data visibility.